Dr Reddy’s Laboratories has moved higher by 2.2% at Rs 1,879 on NSE after the company announced that it has launched Zoledronic acid injection in the US market following approval by the US health regulator.
“The company has launched Zoledronic acid injection (5 mg/100 ml) in the US market on April 3, 2013, following the approval by the United States Food and Drugs Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The product is a generic version of Reclast (zoledronic acid) injection in the same strength. The company’s injection is available in single use vial for intravenous infusion.
According to IMS health, the Reclast brand had total US sales of approximately $335 million for the most recent twelve months ending February 2013.
The stock opened at Rs 1,835 and hit a low of Rs 1,831 in morning deals. A combined 94,657 shares have changed hands on the counter till 1056 hours on NSE and BSE.
“The company has launched Zoledronic acid injection (5 mg/100 ml) in the US market on April 3, 2013, following the approval by the United States Food and Drugs Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The product is a generic version of Reclast (zoledronic acid) injection in the same strength. The company’s injection is available in single use vial for intravenous infusion.
According to IMS health, the Reclast brand had total US sales of approximately $335 million for the most recent twelve months ending February 2013.
The stock opened at Rs 1,835 and hit a low of Rs 1,831 in morning deals. A combined 94,657 shares have changed hands on the counter till 1056 hours on NSE and BSE.
